Treating Migraine and POTS Together: Medications That Work for Both

One of the most practical insights in dysautonomia medicine is that several medications treat both POTS and migraine simultaneously — and that choosing treatments with dual benefit can simplify regimens, reduce pill burden, and improve outcomes for both conditions. Conversely, some medications that are first-line for one condition can worsen the other. Navigating this landscape requires understanding the pharmacology of both conditions.

Medications with Dual Benefit

Beta-blockers: Propranolol and Metoprolol

Beta-blockers are first-line for both POTS and migraine prevention. Propranolol (non-selective) and metoprolol (cardioselective) reduce heart rate in POTS and reduce migraine frequency through mechanisms that include reduced sympathetic tone, serotonin receptor modulation, and reduced cortical excitability.

For POTS patients with concurrent migraine, propranolol is often the preferred starting point because it has the strongest evidence for migraine prevention among beta-blockers. The typical migraine prevention dose (40–160 mg/day) overlaps well with the POTS dose range. The main limitation is that beta-blockers can worsen orthostatic hypotension in hypovolemic POTS and are contraindicated in asthma.

Ivabradine

Ivabradine (Corlanor) reduces heart rate by blocking the If channel in the sinoatrial node without affecting blood pressure or peripheral vascular resistance. It is increasingly used for POTS and has modest evidence for migraine prevention. It is particularly useful in patients who cannot tolerate beta-blockers due to low blood pressure or asthma.

Amitriptyline (low dose)

Low-dose amitriptyline (10–50 mg at bedtime) is effective for migraine prevention, central sensitization, and sleep disturbance — all common in POTS. It has mild anticholinergic effects that can increase heart rate slightly, which is sometimes beneficial in bradycardic POTS patients. The main limitations are sedation, constipation (problematic in gastroparesis), and orthostatic hypotension at higher doses.

Topiramate

Topiramate is a second-line migraine preventive with modest evidence for POTS (it reduces sympathetic tone and may help with hyperadrenergic POTS). It causes weight loss in most patients — beneficial for IIH-associated migraine but potentially problematic in underweight POTS patients. Cognitive side effects ("dopamax") are common and limit tolerability.

Magnesium

Magnesium deficiency lowers the migraine threshold and is common in POTS patients (due to increased urinary magnesium excretion from sympathetic activation and diuretic use). Magnesium glycinate or malate (400–600 mg/day) reduces migraine frequency and improves autonomic function. It is one of the safest and most underutilized interventions in POTS+migraine.

Riboflavin (Vitamin B2)

Riboflavin 400 mg/day has strong evidence for migraine prevention and supports mitochondrial function — relevant for ME/CFS and POTS patients with mitochondrial dysfunction. It is safe, inexpensive, and causes harmless bright yellow urine.

CoQ10

CoQ10 (300 mg/day) reduces migraine frequency and supports mitochondrial energy production. Particularly relevant for patients with fatigue-predominant POTS and ME/CFS overlap.

Medications to Use with Caution

Triptans. Triptans (sumatriptan, rizatriptan, etc.) are vasoconstrictors and are the standard acute migraine treatment. In most POTS patients, they are safe and effective. However, in hyperadrenergic POTS — where sympathetic tone and vascular resistance are already elevated — triptans can cause significant vasoconstriction and are relatively contraindicated. Gepants (rimegepant, ubrogepant) are preferred for acute migraine treatment in hyperadrenergic POTS.

Verapamil. Verapamil is a calcium channel blocker used for migraine prevention. It lowers blood pressure and heart rate, which can worsen orthostatic hypotension in hypovolemic POTS. Use with caution and close monitoring.

Valproate (Depakote). Valproate is effective for migraine prevention but causes weight gain (problematic in IIH), tremor, and — rarely — hyperammonemia. It is teratogenic and should not be used in women of childbearing age without reliable contraception.

Building a Unified Treatment Plan

The most effective approach for POTS+migraine is to:

1. Start with interventions that benefit both conditions: magnesium, riboflavin, CoQ10, and adequate hydration.
2. Add a beta-blocker (propranolol or metoprolol) if heart rate control is needed and blood pressure is adequate.
3. If migraines persist despite beta-blocker therapy, add a CGRP antibody — these do not interfere with POTS management.
4. For acute migraine treatment, use gepants rather than triptans if there is any concern about vasoconstriction.
5. Address MCAS if present — mast cell stabilization often reduces both migraine and POTS symptoms.

The ChatDys Treatments page allows you to track all of these medications and supplements, log their effects on both your POTS and migraine symptoms, and generate a treatment summary for your physician.